Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge. Speaking on "Bloomberg Open Interest," Bloomberg's Madison Muller also discusses the implications for Novo Nordisk. Video Transcript 00:00 Speaker A Madison, talk to us about Eli Lilly because, to Danny's point, they're one of the few bright spots at least this morning. I mean, talk to us about how much their expansion into pills and other powerful weight loss drugs will drive their future growth. 00:10 Madison Yeah, exactly. Thank you guys so much for having me. I mean, it's another amazing quarter for Lily.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.